1 April 2026 - The April 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The April issue of the Schedule includes has many new/revised listings of note:

• Botulinum toxin type A (Xeomin) - new indication
• Desmopressin acetate (Desmomed) - new formulation
• Durvalumab (Imfinzi) - new indications x 2
• Edarvarone (Radicava) - restriction change
• Elranatamab (Elrexfio) - new medicine
• Fedratinib dihydrochloride monohydrate (Inrebic) - new medicine
• Garadacimab (Andembry) - new medicine
• Givosiran sodium (Givlaari) - new gene therapy
• Mogamulizumab (Poteligeo) new medicine
• Pembrolizumab (Keytruda) - new indications x 3
• Polyethylene glycol with propylene glycol (Systane) - new formulation
• Repotrectinib (Augtyro) - new medicine
• Risdiplam (Evrysdi) - new formulation
• Zilucoplan sodium (Zilbrysq) - new medicine

Read summary of PBS changes